Table of Contents ________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ t ...

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q2 2024 Earnings Conference Call August 2, 2024 8:30 AM ET Company Participants Michael Beaulieu - CFA, VP, IR & Corporate Communications Robert Spignesi - President & CEO Sean Wirtjes - CFO Conference Call Participants Yuko Oku - Morgan Stanley Dan Arias - Stifel Operator Thank you for standing by. My name is Dee and I will be your conference operator today. At this time, I would like to welcome everyone to the Rapid Micro Biosystems Second Quarter 2024 Earnings C ...

Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -3.57%. A quarter ago, it was expected that this company would post a loss of $0.29 per share when it actually produced a loss of $0.31, delivering a surprise of -6.90%. Over the last four quarters, the compa ...

Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2024 Financial Results • Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023 • 150th Growth Direct® system placed with an existing top 15 global pharma customer • First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customer • Gross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to ...

Record second quarter 2024 revenue of $6.6 million, representing growth of 32% compared to the second quarter of 2023 150th Growth Direct® system placed with an existing top 15 global pharma customer First Growth Direct Rapid Sterility system placed with an existing top 10 global pharma customer Gross margin improved by 35 percentage points compared to the second quarter of 2023, and by 24 percentage points compared to the first quarter of 2024 Announces operational efficiency program that is expected to en ...

LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024. About Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mis ...

In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, August 2, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccine ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Numbe ...

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Michael Beaulieu - CFA Vice President, Investor Relations and Corporate Communications Robert Spignesi - President and CEO Sean Wirtjes - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Steven Mah - TD Cowen Operator Thank you for standing by. My name is John, and I will be your conference operator for today. All lines have been placed on mute to prevent any backgro ...

Exhibit 99.1 Rapid Micro Biosystems Reports First Quarter 2024 Financial Results Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023 LOWELL, Mass., May 3, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission crit ...